Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative bacterial pathogen commonly associated with nosocomial infections. Treatment of P. aeruginosa infections is notoriously difficult due to biofilm formation and antibiotic resistance. Antimicrobial peptides (AMPs) are thought to be promising new antimicrobials. Gp28, a phage-derived AMP, is a novel class of characterized phage AMPs with activity against Escherichia coli in a manner similar to the human peptide LL-37. LL-37 exhibits strong antimicrobial activity against P. aeruginosa as well as biofilm disruption and synergy with certain antibiotics posing the question whether gp28 could act similarly.
Methods:
Antibacterial activity of gp28 against P. aeruginosa was established using growth inhibition assays, with minimum inhibitory concentration calculated. Biofilm disruption was assessed using crystal violet staining and scanning electron microscopy. Combined treatment of gp28 with tobramycin against P. aeruginosa was measured using a modified time-kill assay at sublethal concentrations.
Results:
Gp28 inhibits P. aeruginosa planktonic growth, with a minimum inhibitory concentration of 109 μg mL−1 and disrupts established biofilms. We demonstrate that gp28 increases the susceptibility of P. aeruginosa to tobramycin.
Conclusions:
Gp28 demonstrates potential for development as a putative therapeutic agent against a clinically resistant P. aeruginosa strain either alone or in combination with the frontline antibiotic tobramycin.
Get full access to this article
View all access options for this article.
References
1.
El BazeP, ThyssA, VintiH, et al.A study of nineteen immunocompromised patients with extensive skin lesions caused by Pseudomonas aeruginosa with and without bacteremia. Acta Derm Venereol, 1991; 71(5):411–415.
2.
AltoparlakU, ErolS, AkcayMN, et al.The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns, 2004; 30(7):660–664; doi: 10.1016/j.burns.2004.03.005
3.
BieleckiP, GlikJ, KaweckiM, et al.Towards understanding Pseudomonas aeruginosa burn wound infections by profiling gene expression. Biotechnol Lett, 2008; 30(5):777–790; doi: 10.1007/S10529-007-9620-2/FIGURES/1
4.
SadikotRT, BlackwellTS, ChristmanJW, et al.Pathogen–host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med, 2012; 171(11):1209–1223; doi: 10.1164/RCCM.200408-1044SO
5.
DaviesJC. Pseudomonas aeruginosa in cystic fibrosis: Pathogenesis and persistence. Paediatr Respir Rev, 2002; 3(2):128–134; doi: 10.1016/S1526-0550(02)00003-3
StewartPS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol, 2002; 292(2):107–113; doi: 10.1078/1438-4221-00196
8.
BaggeN, SchusterM, HentzerM, et al.Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother, 2004; 48(4):1175–1187; doi: 10.1128/AAC.48.4.1175-1187.2004
9.
YousefpourZ, DavarzaniF, OwliaP. Evaluating of the effects of sub-MIC concentrations of gentamicin on biofilm formation in clinical isolates of Pseudomonas aeruginosa. Iran J Pathol, 2021; 16(4):403–410; doi: 10.30699/IJP.20201.524220.2584
10.
CeriH, OlsonME, StremickC, et al.The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol, 1999; 37(6):1771–1776; doi: 10.1128/JCM.37.6.1771-1776.1999
11.
JavadpourMM, JubanMM, LoWCJ, et al.De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem, 1996; 39(16):3107–3113; doi: 10.1021/JM9509410/SUPPL_FILE/JM3107.PDF
12.
GorrSU, FloryCM, SchumacherRJ. In vivo activity and low toxicity of the second-generation antimicrobial peptide DGL13K. PLoS One, 2019; 14(5):e0216669; doi: 10.1371/JOURNAL.PONE.0216669
13.
MaganaM, PushpanathanM, SantosAL, et al.The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis, 2020; 20(9):e216–e230; doi: 10.1016/S1473-3099(20)30327-3
14.
SinghM, MukhopadhyayK. Alpha-melanocyte stimulating hormone: An emerging anti-inflammatory antimicrobial peptide. Biomed Res Int, 2014; 2014:874610; doi: 10.1155/2014/874610
NandiA, YadavR, SinghA. Phage derived lytic peptides, a secret weapon against Acinetobacter baumannii—An in silico approach. Front Med (Lausanne), 2022; 9:1047752; doi: 10.3389/FMED.2022.1047752/BIBTEX
18.
MirskiT, MizakL, NakoniecznaA, et al.Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs. Ann Agric Environ Med, 2019; 26(2):203–209; doi: 10.26444/AAEM/105390
19.
CzaplewskiL, BaxR, ClokieM, et al.Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis, 2016; 16(2):239–251; doi: 10.1016/S1473-3099(15)00466-1
20.
HoltA, CahillJ, RamseyJ, et al.Phage-encoded cationic antimicrobial peptide required for lysis. J Bacteriol, 2022; 204(1):JB0021421; doi: 10.1128/JB.00214-21
21.
MaitiR, Van DomselaarGH, ZhangH, et al.SuperPose: A simple server for sophisticated structural superposition. Nucleic Acids Res, 2004; 32(suppl_2):W590–W594; doi: 10.1093/NAR/GKH477
22.
JumperJ, EvansR, PritzelA, et al.Highly accurate protein structure prediction with AlphaFold. Nature, 2021; 596(7873):583–589; doi: 10.1038/s41586-021-03819-2
23.
SchrödingerLLC. The PyMOL Molecular Graphics System, Version∼1.8. 2015.
24.
PaharB, MadonnaS, DasA, et al.Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. Vaccines (Basel), 2020; 8(3):1–19; doi: 10.3390/VACCINES8030517
25.
RidyardKE, OverhageJ. The potential of human peptide LL-37 as an antimicrobial and anti-biofilm agent. Antibiotics (Basel), 2021; 10(6); doi: 10.3390/ANTIBIOTICS10060650
Anonymous. EUCAST Disk Diffusion Method for Antimicrobial Susceptibility Testing Antimicrobial susceptibility testing EUCAST disk diffusion method. 2023.
28.
LambertRJW, PearsonJ. Susceptibility testing: Accurate and reproducible Minimum Inhibitory Concentration (MIC) and Non-Inhibitory Concentration (NIC) values. J Appl Microbiol, 2000; 88(5):784–790; doi: 10.1046/J.1365-2672.2000.01017.X
29.
HarrisLG, BexfieldA, NigamY, et al.Disruption of Staphylococcus epidermidis biofilms by medicinal maggot Lucilia sericata excretions/secretions. Int J Artif Organs, 2018; 32(9):555–564; doi: 10.1177/039139880903200904
30.
De La Fuente-NúñezC, KorolikV, BainsM, et al.Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother, 2012; 56(5):2696–2704; doi: 10.1128/AAC.00064-12
31.
PayneJE, DuboisAV, IngramRJ, et al.Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens. Int J Antimicrob Agents, 2017; 50(3):427–435; doi: 10.1016/J.IJANTIMICAG.2017.04.014
32.
WnorowskaU, NiemirowiczK, MyintM, et al.Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58. Antimicrob Agents Chemother, 2015; 59(7):3808–3815; doi: 10.1128/AAC.00421-15
WoudstraC, SørensenAN, Holst SørensenMC, et al.Strategies for developing phages into novel antimicrobial tailocins. Trends Microbiol, 2024; doi: 10.1016/j.tim.2024.03.003
35.
BriersY, WalmaghM, Van PuyenbroeckV, et al.Engineered endolysin-based “Artilysins” to combat multidrug-resistant gram-negative pathogens. mBio, 2014; 5(4):e01379–e01314; doi: 10.1128/MBIO.01379-14
36.
KimS, LeeD-W, JinJ-S, et al.Antimicrobial activity of LysSS, a novel phage endolysin, against Acinetobacter baumannii and Pseudomonas aeruginosa. J Glob Antimicrob Resist, 2020; 22:32–39; doi: 10.1016/j.jgar.2020.01.005
37.
GuoM, FengC, RenJ, et al.A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa. Front Microbiol, 2017; 8:293; doi: 10.3389/FMICB.2017.00293/BIBTEX
38.
SmartM, RajagopalA, LiuWK, et al.Opposing effects of cationic antimicrobial peptides and divalent cations on bacterial lipopolysaccharides. Phys Rev E, 2017; 96(4–1):042405; doi: 10.1103/PHYSREVE.96.042405/FIGURES/5/MEDIUM
39.
RuanX, Monjarás FeriaJ, HamadM, et al.Escherichia coli and Pseudomonas aeruginosa lipopolysaccharide O-antigen ligases share similar membrane topology and biochemical properties. Mol Microbiol, 2018; 110(1):95–113; doi: 10.1111/MMI.14085
40.
TorresMDT, SothiselvamS, LuTK, et al.Peptide design principles for antimicrobial applications. J Mol Biol, 2019; 431(18):3547–3567; doi: 10.1016/J.JMB.2018.12.015
41.
TorresNI, NollKS, XuS, et al.Safety, formulation and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus Type 1. Probiotics Antimicrob Proteins, 2013; 5(1):26–35; doi: 10.1007/S12602-012-9123-X/FIGURES/7
42.
LeeK, YoonSS. Pseudomonas aeruginosa biofilm, a programmed bacterial life for fitness. J Microbiol Biotechnol, 2017; 27(6):1053–1064; doi: 10.4014/JMB.1611.11056
43.
ConlonBP, RoweSE, LewisK. Persister cells in biofilm associated infections. Adv Exp Med Biol, 2015; 831:1–9; doi: 10.1007/978-3-319-09782-4_1
44.
HughesG, WebberMA. Novel approaches to the treatment of bacterial biofilm infections. Br J Pharmacol, 2017; 174(14):2237–2246; doi: 10.1111/BPH.13706
45.
BatoniG, MaisettaG, EsinS. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta, 2016; 1858(5):1044–1060; doi: 10.1016/J.BBAMEM.2015.10.013
46.
LeeCC, SunY, QianS, et al.Transmembrane pores formed by human antimicrobial peptide LL-37. Biophys J, 2011; 100(7):1688–1696; doi: 10.1016/J.BPJ.2011.02.018
47.
FengX, SambanthamoorthyK, PalysT, et al.The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides (NY), 2013; 49:131–137; doi: 10.1016/J.PEPTIDES.2013.09.007
48.
IacobSA, IacobDG. Antibacterial function of the human cathelicidin-18 peptide (LL-37) between theory and practice. PPL, 2014; 21(12):1247–1256; doi: 10.2174/0929866521666140805124855
49.
Segev-ZarkoL, Saar-DoverR, BrumfeldV, et al.Mechanisms of biofilm inhibition and degradation by antimicrobial peptides. Biochem J, 2015; 468(2):259–270; doi: 10.1042/BJ20141251
50.
DuplantierAJ, van HoekML. The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. Front Immunol, 2013; 4(JUL):143; doi: 10.3389/FIMMU.2013.00143
51.
ReynoldsD, KollefM. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: An update. Drugs, 2021; 81(18):2117–2131; doi: 10.1007/S40265-021-01635-6
52.
VestergaardM, PaulanderW, MarvigRL, et al.Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents, 2016; 47(1):48–55; doi: 10.1016/J.IJANTIMICAG.2015.09.014
53.
TammaPD, CosgroveSE, MaragakisLL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev, 2012; 25(3):450–470; doi: 10.1128/CMR.05041-11
54.
BanerjeeD, StableforthD. The treatment of respiratory Pseudomonas infection in cystic fibrosis: What drug and which way? Drugs, 2000; 60(5):1053–1064; doi: 10.2165/00003495-200060050-00006/FIGURES/TAB2
55.
DoslerS, KaraaslanE. Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides. Peptides (NY), 2014; 62:32–37; doi: 10.1016/J.PEPTIDES.2014.09.021
56.
GeitaniR, Ayoub MoubareckC, TouquiL, et al.Cationic antimicrobial peptides: Alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol, 2019; 19(1):54–12; doi: 10.1186/S12866-019-1416-8/TABLES/3
57.
RidyardKE, ElsawyM, MattrasinghD, et al.Synergy between human peptide LL-37 and Polymyxin B against planktonic and biofilm cells of Escherichia coli and Pseudomonas aeruginosa. Antibiotics (Basel), 2023; 12(2):389; doi: 10.3390/ANTIBIOTICS12020389
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
